Anti-Clostridium botulinum Toxin B Antibody (18914)

$620.00

Host	Quantity	Applications	Species Reactivity	Data Sheet
Mouse	500ul	ICC/IF,ELISA,RIA	Clostridium Botulinum Toxin B

SKU: 18914 Categories: Antibody Products, Infectious Disease Antibodies, Products

Overview

Product Name Anti-Clostridium botulinum Toxin B Antibody (18914)

Description Anti-Clostridium botulinum Toxin B Mouse Monoclonal Antibody

Target Clostridium botulinum Toxin B

Species Reactivity Clostridium Botulinum Toxin B

Applications ICC/IF,ELISA,RIA

Host Mouse

Clonality Monoclonal

Clone ID B363M

Isotype IgG

Immunogen Synthetic peptide corresponding to aa 1278-1291 at the C-terminus of Clostridium botulinum Toxin B.

Properties

Form Liquid

Concentration Lot Specific

Formulation PBS, pH 7.4.

Buffer Formulation Phosphate Buffered Saline

Buffer pH pH 7.4

Format Purified

Purification Purified by immunoaffinity chromatography

Specificity This antibody recognizes C. botulinum Toxin B. It does not cross-react with toxins A, C, E, or F.

Target Name Botulinum neurotoxin type B

Target ID Clostridium botulinum Toxin B

Uniprot ID P10844

Gene Name botB

Sequence Location [Botulinum neurotoxin type B]: Secreted, Host cell junction, host synapse, host presynaptic cell membrane

Biological Function [Botulinum neurotoxin type B]: Botulinum toxin causes flaccid paralysis by inhibiting neurotransmitter (acetylcholine) release from the presynaptic membranes of nerve terminals of the eukaryotic host skeletal and autonomic nervous system, with frequent heart or respiratory failure. Precursor of botulinum neurotoxin B which has 2 coreceptors; complex polysialylated gangliosides found on neural tissue and specific membrane-anchored proteins found in synaptic vesicles (PubMed:17185412, PubMed:17167421, PubMed:17167418, PubMed:23807078). Receptor proteins are exposed on host presynaptic cell membrane during neurotransmitter release, when the toxin heavy chain (HC) binds to them (PubMed:14504267). Upon synaptic vesicle recycling the toxin is taken up via the endocytic pathway (PubMed:14504267). When the pH of the toxin-containing endosome drops a structural rearrangement occurs so that the N-terminus of the HC forms pores that allows the light chain (LC) to translocate into the cytosol (PubMed:3856850). Once in the cytosol the disulfide bond linking the 2 subunits is reduced and LC cleaves its target protein on synaptic vesicles, preventing their fusion with the cytoplasmic membrane and thus neurotransmitter release. Binds to host peripheral neuronal presynaptic membranes via synaptotagmins 1 and 2 (SYT1 and SYT2) (PubMed:8144634, PubMed:14504267). Toxin binds to the membrane proximal extra-cytoplasmic region of host SYT1 and SYT2 that is transiently exposed outside of cells during exocytosis; exogenous gangliosides enhance binding and subsequent uptake of toxin into host cells (PubMed:14504267, PubMed:15123599). Toxin uptake into neural cells requires stimulation (incubation with K(+) to stimulate SYT protein receptor exposure); subsequently the toxin colocalizes with its receptor in host cells with a concomitant decrease in target protein (synaptobrevin-2/VAMP2) immunoreactivity (PubMed:14504267). Toxin uptake can be blocked by the appropriate synaptotagmin protein fragments and gangliosides in cell culture and in mice (PubMed:14504267, PubMed:15123599). BoNT/B is a 'coincidence detector'; it requires simultaneous binding to coreceptor GT1b and low pH to transform into a membrane-bound, oligomeric channel (PubMed:21925111, PubMed:22720883). Whole toxin only has protease activity after reduction which releases LC (PubMed:1331807, PubMed:7803399). {PubMed:1331807, PubMed:14504267, PubMed:15123599, PubMed:17167418, PubMed:17167421, PubMed:17185412, PubMed:21925111, PubMed:22720883, PubMed:23807078, PubMed:3856850, PubMed:7803399, PubMed:8144634}.; [Botulinum neurotoxin B light chain]: Has proteolytic activity (PubMed:1331807). After translocation into the eukaryotic host cytosol, inhibits neurotransmitter release by acting as a zinc endopeptidase that cleaves the '76-Gln-|-Phe-77' bond of synaptobrevin-2/VAMP2, blocking neurotransmitter release (PubMed:1331807, PubMed:7803399). In vitro the LC only has protease activity after reduction (PubMed:1331807, PubMed:7803399). {PubMed:1331807, PubMed:7803399}.; [Botulinum neurotoxin B heavy chain]: Responsible for host epithelial cell transcytosis, host nerve cell targeting and translocation of light chain (LC) into host cytosol. Composed of 3 subdomains; the translocation domain (TD), and N-terminus and C-terminus of the receptor-binding domain (RBD). The N-terminus of the TD wraps an extended belt around the perimeter of the LC; it does not seem to protect the active site, but might prevent premature LC dissociation from the translocation channel and protect toxin prior to translocation (PubMed:10932256, PubMed:17167418). Has 2 coreceptors; complex gangliosides found primarily on neural tissue and host synaptotagmin-1 and -2 (SYT1 and SYT2) which bind simultaneously to adjacent but separate sites at the tip of the HC (PubMed:8144634, PubMed:17185412, PubMed:17167421, PubMed:17167418, PubMed:23807078). HC alone partially prevents uptake of whole toxin by neural cells, and delays paralysis onset by 160% (PubMed:10413679). Binding probably positions the TD for integration into the synaptic vesicle membrane (PubMed:17167418, PubMed:23807078). The HC forms channels at low pH that mediate transport of the light chain (LC) from the endocytic vesicle to the cytosol (PubMed:3856850). Binds gangliosides GD1b and GT1b (PubMed:10413679, PubMed:14731268). Gangliosides are not only a coreceptor, but also required for uptake into nerve cells (PubMed:21925111, PubMed:17167418). HC alone binds to host receptor proteins SYT1 and SYT2 (PubMed:14504267, PubMed:15123599, PubMed:17185412, PubMed:19650874). Interaction with SYT1 protein does not require SYT1 glycosylation (PubMed:19476346). The HC C-terminus (approximately residues 1079-1291) interacts with host SYT2 (PubMed:15123599, PubMed:17167421, PubMed:17167418, PubMed:23807078). Has higher affinity for SYT2 than SYT1 (PubMed:17185412, PubMed:17167421). Significantly decreases uptake and toxicity of whole BoNT/B and BoNT/G (PubMed:19650874). {PubMed:10413679, PubMed:10932256, PubMed:14504267, PubMed:14731268, PubMed:15123599, PubMed:17167418, PubMed:17167421, PubMed:17185412, PubMed:19650874, PubMed:23807078, PubMed:8144634, PubMed:21925111, PubMed:3856850}.

Research Areas Infectious Disease

Background Clostridium botulinum, an anaerobic, gram-positive, spore-forming rod commonly found on plants, in soil, water, and the intestinal tracts of animals, produces eight antigenically distinguishable exotoxins (A, B, C1, C2, D, E, F and G). Type A is the most potent toxin, followed by types B and F. All botulinum neurotoxins are produced as single polypeptide chains of ~150kDa comprised of a heavy (H) chain and a light (L) chain of roughly 100 and 50kDa, respectively, linked by a disulfide bond. The heavy (H) chain of the toxin binds selectively and irreversibly to high affinity receptors at the presynaptic surface of cholinergic neurones, and the toxin-receptor complex is taken up into the cell by endocytosis where the disulfide bond between the two chains is cleaved. The light (L) chain interacts with different proteins in the nerve terminals to prevent fusion of acetylcholine vesicles with the cell membrane.

Handling

Storage This antibody is stable for at least one (1) year at -20° to -70°C. Store product in appropriate aliquots to avoid multiple freeze-thaw cycles.

Dilution Instructions Dilute in PBS or medium that is identical to that used in the assay system.

Application Instructions ELISA, Immunocytochemistry, Immunofluorescence

End users should determine optimal dilutions for their applications.

Data Sheet